umio.io

What It Is

Umio is a health innovation company based in Oxford, UK. Its core proposition is to help health systems, healthcare providers, and enterprises understand “Real Lived Experience” (RLX)—the kind of day-to-day reality that traditional clinical data, satisfaction surveys, or demographic segmentation often fail to capture. Judging from its website, Umio is not a conventional consulting firm, nor is it a standardized lightweight SaaS product. Rather, it appears to be a professional services system combining a research framework, an AI platform, and an innovation methodology.

Core Features and Product Format

Umio’s offering has three main layers. First is its RLX theory and Health Ecosystem Value Design framework, used to understand the relationships, emotions, environments, and time dimensions involved in chronic illness, care, and everyday life. Second is the Bergson AI platform, which can quickly generate Real Lived Outcomes, experience ecosystems, narratives, and design inspiration for any chronic condition, population, or region. Third is the RLX Innovation Process, which turns experience insights into opportunities for strategy, design, market access, and growth. In addition, Umio licenses the Ooex real-time lived experience platform, which is used to capture users’ expressive moments, activities, patterns, and thresholds, while supporting reflection with clinical or community partners.

Pricing, Trials, and Integrations

The website does not disclose plans, pricing, free trials, payment methods, APIs, third-party integrations, permission management, or deployment models. From a SaaS procurement perspective, transparency is therefore limited. At present, Umio is better evaluated as a project-based, consulting-led, platform partnership, or customized innovation process offering, rather than as a software subscription that can be purchased directly through self-service.

Pros and Cons

Its strengths lie in its highly focused positioning, making it suitable for complex scenarios such as chronic pain, Long COVID, neurodiversity, mental health, progressive diseases, multimorbidity, addiction recovery, and stigmatized conditions. It also has project experience across pharmaceuticals, medical devices, the NHS, government, and charities. The limitations are that its conceptual system is relatively abstract and requires a fairly mature health innovation, research, and design capability on the buyer’s side. At the same time, the website lacks key enterprise software information around security and compliance, data governance, team permissions, and similar requirements.

Who It’s For and Access from China

Umio is suitable for healthcare enterprises, pharmaceutical and medical device companies, health systems, government projects, digital health platforms, and innovation teams, especially for deep patient experience research, product innovation, service design, and market strategy. The website does not provide information on access from China, so this remains unknown; payment methods are also not disclosed. For teams in China considering procurement, it is advisable to confirm network availability, contracting and payment routes, cross-border data requirements, and medical/health data compliance needs. Local healthcare consulting firms, patient insight research providers, and digital health service design agencies should also be evaluated as alternatives.